Stay updated on Autologous TIL MDA-TIL in Recurrent Cancer Clinical Trial

Sign up to get notified when there's something new on the Autologous TIL MDA-TIL in Recurrent Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Autologous TIL MDA-TIL in Recurrent Cancer Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    0.7%
    Check dated 2025-06-19T19:17:27.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-05T11:01:09.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    The web page has been updated to reflect a modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    1%
    Check dated 2025-05-29T05:45:31.000Z thumbnail image
  5. Check
    52 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-04-30T13:52:44.000Z thumbnail image
  6. Check
    59 days ago
    Change Detected
    Summary
    The webpage has updated key results related to ovarian cancer, including new reporting dates and metrics for evaluating treatment outcomes, while removing outdated information on response rates and survival metrics.
    Difference
    20%
    Check dated 2025-04-23T08:21:58.000Z thumbnail image
  7. Check
    66 days ago
    Change Detected
    Summary
    The webpage has undergone significant updates, including the addition of new clinical trial identifiers, collaborators, and a revision number, while removing detailed descriptions of the trial's objectives, treatment protocols, and inclusion/exclusion criteria.
    Difference
    46%
    Check dated 2025-04-16T01:46:38.000Z thumbnail image

Stay in the know with updates to Autologous TIL MDA-TIL in Recurrent Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Autologous TIL MDA-TIL in Recurrent Cancer Clinical Trial page.